SCHEMBL1829423

SCHEMBL1829423

C[C@](O)(C(=O)O)[C@H](O)[C@H](O)CO

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.38
ALDH1A1 P00352 1/20 0.38
PDE4A P27815 1/20 0.37
LMNA P02545 2/20 0.34
TET2 Q6N021 1/20 0.34
USP2 O75604 1/20 0.34
SLCO1B1 Q9Y6L6 1/20 0.34
OR51E2 Q9H255 1/20 0.33
HMGCR P04035 1/20 0.32
CHRM1 P11229 1/20 0.32
TBXA2R P21731 1/20 0.32
ADRA1A P35348 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
PGD P52209 1/20 0.32
ACACB O00763 1/20 0.31
ACACA Q13085 1/20 0.31
CYP2D6 P10635 1/20 0.31
CYP2C19 P33261 1/20 0.31
HIF1A Q16665 1/20 0.31
TDP1 Q9NUW8 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9312516 1.00 TSHR (0.38) TSHRALDH1A1PDE4ALMNATET2
SCHEMBL6295932 1.00 TSHR (0.38) TSHRALDH1A1PDE4ALMNATET2
SCHEMBL2933991 0.87 PDE4A (0.43) TSHRALDH1A1PDE4ALMNATET2
SCHEMBL28426564 0.87 PDE4A (0.43) TSHRALDH1A1PDE4ALMNATET2
Hydrochloric Acid SCHEMBL19520560 0.85 PDE4A (0.42) TSHRALDH1A1PDE4ALMNATET2
SCHEMBL28892067 0.82 PDE4A (0.32) PDE4ALMNAUSP2SLCO1B1L3MBTL1
SCHEMBL18954089 0.82 PDE4A (0.32) PDE4ALMNAUSP2SLCO1B1L3MBTL1
SCHEMBL28153901 0.80 PDE4A (0.31) PDE4ALMNAL3MBTL1
SCHEMBL27957989 0.80 PDE4A (0.31) PDE4ALMNAL3MBTL1
SCHEMBL28244015 0.79 PDE4A (0.38) TSHRALDH1A1PDE4ALMNATET2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0156172-A2 Method for the preparation of anthracyclinones LABORATOIRES HOECHST S.A. (FR) 1985-10-02 EP claimed
EP-2319853-B1 Process for the production of 2'-branched nucleosides IDENIX PHARMACEUTICALS INC (US) 2014-03-12 EP disclosed
EP-2319853-A1 Process for the production of 2'-branched nucleosides Idenix (Cayman) Limited (KY) 2011-05-11 EP disclosed
US-7598373-B2 Process for the production of 2-C-methyl-D-ribonolactone IDENIX PHARMACEUTICALS, INC. (US) 2009-10-06 US disclosed
EP-1585529-A4 PROCESS FOR THE PRODUCTION OF 2'-BRANCHED NUCLEOSIDES IDENIX CAYMAN LTD (KY) 2008-05-28 EP disclosed
WO-2007025304-A2 PROCESS FOR PREPARING SACCHARINIC ACIDS AND LACTONES THE CHANCELLORS, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD (GB) 2007-03-01 WO disclosed
EP-1585529-A2 PROCESS FOR THE PRODUCTION OF 2'-BRANCHED NUCLEOSIDES Idenix (Cayman) Limited (KY) 2005-10-19 EP disclosed
US-20050020825-A1 Process for the production of 2'-branched nucleosides IDENIX PHARMACEUTICALS LLC 2005-01-27 US disclosed
WO-2004052899-A2 PROCESS FOR THE PRODUCTION OF 2'-BRANCHED NUCLEOSIDES IDENIX (CAYMAN) LIMITED (KY) 2004-06-24 WO disclosed
US-6562514-B1 Stabilized vanadium electrolyte solutions for all-vanadium redox cells and batteries PINNACLE VRB LIMITED (AU) 2003-05-13 US disclosed
US-6468688-B2 CHARGING, DISCHARGING EFFICIENCY; VANADIUM ELECTROLYTE PINNACLE VRB LIMITED (AU) 2002-10-22 US disclosed
US-20010028977-A1 Charging, discharging efficiency; vanadium electrolyte JD HOLDING INC. (KY) 2001-10-11 US disclosed
US-6143443-A ALL-VANADIUM REDOX BATTERY, COMPRISING THE STABILIZED ELECTROLYTE PINNACLE ARB LIMITED (AU) 2000-11-07 US disclosed
EP-0829104-A1 HIGH ENERGY DENSITY VANADIUM ELECTROLYTE SOLUTIONS, METHODS OF PREPARATION THEREOF AND ALL-VANADIUM REDOX CELLS AND BATTERIES CONTAINING HIGH ENERGY VANADIUM ELECTROLYTE SOLUTIONS UNISEARCH LIMITED (AU) 1998-03-18 EP disclosed
EP-0729648-A4 STABILISED ELECTROLYTE SOLUTIONS, METHODS OF PREPARATION THEREOF AND REDOX CELLS AND BATTERIES CONTAINING STABILISED ELECTROLYTE SOLUTIONS UNISEARCH LTD (AU) 1997-01-02 EP disclosed
WO-1996035239-A1 HIGH ENERGY DENSITY VANADIUM ELECTROLYTE SOLUTIONS, METHODS OF PREPARATION THEREOF AND ALL-VANADIUM REDOX CELLS AND BATTERIES CONTAINING HIGH ENERGY VANADIUM ELECTROLYTE SOLUTIONS UNISEARCH LIMITED (AU) 1996-11-07 WO disclosed
EP-0729648-A1 STABILISED ELECTROLYTE SOLUTIONS, METHODS OF PREPARATION THEREOF AND REDOX CELLS AND BATTERIES CONTAINING STABILISED ELECTROLYTE SOLUTIONS UNISEARCH LIMITED (AU) 1996-09-04 EP disclosed
WO-1995012219-A1 STABILISED ELECTROLYTE SOLUTIONS, METHODS OF PREPARATION THEREOF AND REDOX CELLS AND BATTERIES CONTAINING STABILISED ELECTROLYTE SOLUTIONS UNISEARCH LIMITED (AU) 1995-05-04 WO disclosed
EP-0156172-A2 Method for the preparation of anthracyclinones LABORATOIRES HOECHST S.A. (FR) 1985-10-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050020825-A1 Process for the production of 2'-branched nucleosides RNGTT, MTAP, NSUN2 TSHR 4533/4885ALDH1A1 2027/4885PDE4A 458/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.